Higher exposure of AFM24 linked to better outcomes in NSCLC patients - AACR presentation by Affimed N.V. (Nasdaq: AFMD) in Germany.

Unusual Whales
2025.04.29 14:17
In Mannheim, Germany, on April 29, 2025, Affimed N.V. shared insights at the 2025 Annual Meeting of the American Association for Cancer Research. The company, trading as Nasdaq: AFMD, highlighted an exposure-outcome analysis of its innovative innate cell engager, AFM24. This presentation focused on patients with advanced or metastatic non-small cell lung cancer (NSCLC). Affimed N.V., a clinical-stage immuno-oncology firm dedicated to empowering patients in battling cancer, showcased these findings in a poster session.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer